Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorRUBIN, Sebastien
dc.contributor.authorORIEUX, Arthur
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPREZELIN-REYDIT, Mathilde
dc.contributor.authorGARRIC, Antoine
dc.contributor.authorPICARD, Yoann
dc.contributor.authorMELLATI, Nouchan
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLE GALL, Lisa
IDREF: 222223472
dc.contributor.authorDEWITTE, Antoine
hal.structure.identifierCentre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]
dc.contributor.authorPREVEL, Renaud
hal.structure.identifierCentre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]
dc.contributor.authorGRUSON, Didier
dc.contributor.authorLOUIS, Guillaume
hal.structure.identifierCentre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]
dc.contributor.authorBOYER, Alexandre
dc.date.accessioned2024-03-13T12:12:00Z
dc.date.available2024-03-13T12:12:00Z
dc.date.issued2024-02-13
dc.identifier.issn2110-5820 (Print) 2110-5820 (Electronic) 2110-5820 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/188781
dc.description.abstractEnBACKGROUND: Acute kidney injury (AKI) in intensive care unit (ICU) patients with severe COVID-19 is common (> 50%). A specific inflammatory process has been suggested in the pathogenesis of AKI, which could be improved by dexamethasone (DXM). In a small monocenter study (n = 100 patients), we reported a potential protective effect of DXM on the risk of AKI. This study aimed to investigate the preventive impact of DXM on AKI in a multicenter study of patients with severe COVID-19. METHODS: We conducted a multicenter study in three French ICUs from March 2020 to August 2021. All patients admitted to ICU for severe COVID-19 were included. Individuals with preexistent AKI or DXM administration before admission to ICU were excluded. While never used during the first wave, DXM was used subsequently at ICU entry, providing two treatment groups. Multivariate Cause-specific Cox models taking into account changes in ICU practices over time, were utilized to determine the association between DXM and occurrence of AKI. RESULTS: Seven hundred and ninety-eight patients were included. Mean age was 62.6 +/- 12.1 years, 402/798 (50%) patients had hypertension, and 46/798 (6%) had previous chronic kidney disease. Median SOFA was 4 [3-6] and 420/798 (53%) required invasive mechanical ventilation. ICU mortality was 208/798 (26%). AKI was present in 598/798 (75%) patients: 266/598 (38%), 163/598 (27%), and 210/598 (35%) had, respectively, AKI KDIGO 1, 2, 3, and 61/598 (10%) patients required renal replacement therapy. Patients receiving DXM had a significantly decreased hazard of AKI occurrence compared to patients without DXM (HR 0.67; 95CI 0.55-0.81). These results were consistent in analyses that (1) excluded patients with DXM administration to AKI onset delay of less than 12 h, (2) incorporating the different 'waves' of the COVID-19 pandemic. CONCLUSIONS: DXM was associated with a decrease in the risk of AKI in severe COVID-19 patients admitted to ICU. This supports the hypothesis that the inflammatory injury of AKI may be preventable.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAcute kidney injury
dc.subject.enIntensive care unit
dc.subject.enCOVID-19
dc.subject.enDexamethasone
dc.title.enImpact of dexamethasone in severe COVID-19-induced acute kidney injury: a multicenter cohort study
dc.title.alternativeAnn Intensive Careen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s13613-024-01258-6en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38349530en_US
bordeaux.journalAnnals of Intensive Careen_US
bordeaux.page26en_US
bordeaux.volume14en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.teamBIOSTAT_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04502801
hal.version1
hal.date.transferred2024-03-13T12:12:02Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Annals%20of%20Intensive%20Care&rft.date=2024-02-13&rft.volume=14&rft.issue=1&rft.spage=26&rft.epage=26&rft.eissn=2110-5820%20(Print)%202110-5820%20(Electronic)%202110-5820%20(Linking)&rft.issn=2110-5820%20(Print)%202110-5820%20(Electronic)%202110-5820%20(Linking)&rft.au=RUBIN,%20Sebastien&ORIEUX,%20Arthur&PREZELIN-REYDIT,%20Mathilde&GARRIC,%20Antoine&PICARD,%20Yoann&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée